Close Menu

NEW YORK – 23andMe has laid off approximately 100 employees, about 14 percent of its workforce, the direct-to-consumer genetic testing company confirmed on Thursday.

According to a spokesperson, the layoffs occurred across the company's consumer business, which is being restructured, but did not affect its therapeutics business.

Going forward, 23andMe will focus its activities on its core businesses, consumer genomics and therapeutics, and plans to scale back on non-core activities, such as clinical trials, the spokesperson said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.

According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.

In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.